SCHEMBL19974744

SCHEMBL19974744

Cc1ccc(S(=O)(=O)NC(C)C(O)C(=O)NCC2CC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.64
ALDH1A1 P00352 9/20 0.51
MEN1 O00255 4/20 0.51
CYP2C9 P11712 1/20 0.51
NPY5R Q15761 1/20 0.51
HSD17B10 Q99714 2/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 1/20 0.49
LMNA P02545 1/20 0.47
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ATM Q13315 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974908 0.89 KMT2A (0.52) KMT2AALDH1A1MEN1NPY5RHTT
SCHEMBL21176298 0.89 KMT2A (0.52) KMT2AALDH1A1MEN1LMNASMN1; SMN2
SCHEMBL19975337 0.89 KMT2A (0.54) KMT2AALDH1A1MEN1NPY5RHSD17B10
SCHEMBL19975436 0.83 KMT2A (0.48) KMT2AALDH1A1MEN1NPY5RPOLB
SCHEMBL19974832 0.81 ITGAV (0.44) KMT2AALDH1A1MEN1NPY5RPOLB
SCHEMBL19974713 0.79 KMT2A (0.59) KMT2AALDH1A1MEN1CYP2C9NPY5R
SCHEMBL19975243 0.78 KMT2A (0.45) KMT2AALDH1A1MEN1CYP2C9NPY5R
SCHEMBL19975144 0.78 MAPK14 (0.49) KMT2AALDH1A1MEN1HPGDL3MBTL1
SCHEMBL15660975 0.77 ALDH1A1 (0.57) ALDH1A1CYP2C9NPY5RHSD17B10TSHR
SCHEMBL15661878 0.77 ALDH1A1 (0.57) ALDH1A1CYP2C9NPY5RHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885ALDH1A1 2271/4885MEN1 4331/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C KMT2A 4177/4885ALDH1A1 2673/4885MEN1 4361/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885ALDH1A1 2271/4885MEN1 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.